Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.
about
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitusRisk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitusRenal effects of dapagliflozin in patients with type 2 diabetesNephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitusUpdate on the treatment of type 2 diabetes mellitusSodium-Glucose Cotransporter 2 (SGLT2) Inhibitors from Natural Products: Discovery of Next-Generation Antihyperglycemic AgentsImpact of sodium-glucose cotransporter 2 inhibitors on blood pressureThe Use of SGLT-2 Inhibitors in Type 2 Diabetes and Heart FailureDiabetic Kidney Disease: Pathophysiology and Therapeutic TargetsBenefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-AnalysisEffect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal modelsDiabetic nephropathy - Epidemiology in Asia and the current state of treatmentEffects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials.Optimal Pharmacologic Treatment Strategies in Obesity and Type 2 DiabetesThe management of type 2 diabetic patients with hypoglycaemic agentsThe role of kidney in glucose homeostasis--SGLT2 inhibitors, a new approach in diabetes treatment.Sodium-Glucose linked transporter 2 (SGLT2) inhibitors--fighting diabetes from a new perspective.Patient Characteristics are not Associated with Clinically Important Differential Response to Dapagliflozin: a Staged Analysis of Phase 3 Data.Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials.Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients.Efficacy and Safety of SGLT2 Inhibitors in Reducing Glycated Hemoglobin and Weight in Emirati Patients With Type 2 Diabetes.Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes.The Relationship between Increases in Morning Spot Urinary Glucose Excretion and Decreases in HbA1C in Patients with Type 2 Diabetes After Taking an SGLT2 Inhibitor: A Retrospective, Longitudinal Study.Novel and emerging diabetes mellitus drug therapies for the type 2 diabetes patientEffects of Six Kinds of Sodium-Glucose Cotransporter 2 Inhibitors on Metabolic Parameters, and Summarized Effect and Its Correlations With Baseline DataNovel SGLT2 inhibitor: first-in-man studies of antisense compound is associated with unexpected renal effects.Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitus.Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial.Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus.Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet.Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitusLong-term efficacy and safety of sodium-glucose cotransporter-2 inhibitors as add-on to metformin treatment in the management of type 2 diabetes mellitus: A meta-analysis.Current therapies and emerging drugs in the pipeline for type 2 diabetes.Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications.Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial.Update on developments with SGLT2 inhibitors in the management of type 2 diabetesSGLT-2 inhibitors in development for type 2 diabetes treatmentDapagliflozin for the treatment of type 2 diabetes.
P2860
Q24235718-DCB29045-972C-499F-BBA6-5F6AB2F6473CQ24240522-C8C1A00B-8961-450B-A0AD-CEAD600450F9Q24564811-F160BE9F-0E9D-42F3-B0F3-C94A83108178Q26777994-C7F6DD8C-AC56-418F-9296-3B6EEA6F39E3Q26782225-086B66F3-A37A-4011-A031-6086E2395E3BQ28073342-E16FA2F3-C211-46ED-A8FA-18073044B499Q28074843-14827282-1396-42D0-9121-6AE491E23C5BQ28080114-2450A498-1212-4FEE-9DFE-D2C6A20614D1Q28082343-2FE36631-7BAD-44E1-93DC-91EE5ECF53B2Q28086840-CB3B7BB5-0F73-4245-B1F6-36960D0324A7Q28553482-D1D87AC6-BF70-4B8D-BCD1-3B0B29E19620Q28732080-D6735C7B-EF08-487E-ACC8-18B763462D1DQ28742785-80F11AFD-71F0-4D3D-8465-1C2BD27ABDF2Q30248634-02060CEF-FE64-4FC2-8B5F-5D70A9C90E35Q30377441-7F1E8F14-F15B-41E9-92FB-7C91530434C6Q30417363-506965F2-4A79-4A24-9518-060995027DB9Q30663494-5E8C5334-7453-40AF-BF1A-70AC7479B9FFQ30833760-8A945E97-5805-4D49-A5A9-C558F69E26A8Q30877953-1297F586-091A-40AA-BEE3-8BCE640B9D95Q33166813-34F523F6-81D9-4B85-B40B-7CC12371BBE3Q33354192-40BABA6C-152F-48A2-BCB0-19555E01770BQ33451134-C6C49059-157B-406E-ADBB-20DC0268E61CQ33625207-D74F9A4D-14A0-477D-A8AA-6D5D5FB4E475Q33625568-E223F9D5-C980-4F0D-96AC-7C75B4E2DFEEQ33732583-CD71B5F9-C3C5-4A21-8F24-2C480EEC6ECEQ33759570-63D6F9A1-0FD2-4F37-A82B-40ADA0E04F5EQ33763316-95A39BA3-C10C-4645-87A2-5DB2A5A9730FQ33771405-D905F4BA-7CB5-41F8-894F-8665A06BD0B1Q33785128-B045F82D-A261-4A08-87AC-42FE97911A0FQ33785136-13719DE1-F314-41E2-AA2F-54F833964684Q33802278-3F69D52D-F97E-4463-8CC5-1F9E37CB4753Q33857698-3016AC47-2D6F-4536-97AB-84C00F02DAB2Q33871321-8D7372E1-2F5D-490E-BE32-BCBC43FA0163Q33885732-21070C17-E415-470B-AAAC-083150BA3DE4Q33928941-F5196BC3-19D4-49F1-8302-3440A7055C4FQ34120717-51226761-5FDD-466F-8622-41162814734CQ34153496-3A6FDA0A-87DD-4D40-9994-356F6FFC2836Q34198692-EB11CBE2-692E-4FBA-8A74-3D900995F71BQ34248505-31D53816-6E32-4697-A791-3C4BF0272A5BQ34262543-490E1C00-2D0F-4F33-9F2B-3342A6138055
P2860
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.
@en
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.
@nl
type
label
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.
@en
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.
@nl
prefLabel
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.
@en
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.
@nl
P2093
P2860
P921
P356
P1433
P1476
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.
@en
P2093
Enrique Morales
Fred T Fiedorek
James F List
Vincent Woo
Weihua Tang
P2860
P304
P356
10.2337/DC08-1863
P407
P577
2008-12-29T00:00:00Z